Zoetis Inc (ZTS) USD0.01

Sell:$160.47Buy:$160.48$3.04 (1.93%)

Prices delayed by at least 15 minutes
Sell:$160.47
Buy:$160.48
Change:$3.04 (1.93%)
Deal now
Prices delayed by at least 15 minutes
Sell:$160.47
Buy:$160.48
Change:$3.04 (1.93%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

Key people

Kristin C. Peck
Chief Executive Officer, Director
Wetteny N. Joseph
Chief Financial Officer, Executive Vice President
Jared Shriver
President, U.S. Operations
Roxanne Lagano
Executive Vice President, Chief Human Resource Officer, Global Operations, Interim General Counsel, Corporate Secretary
Keith Sarbaugh
Executive Vice President, Chief Digital and Technology Officer
Nicholas Ashton
Executive Vice President, President - Global Manufacturing and Supply
Jeannette Ferran Astorga
Executive Vice President - Corporate Affairs, Communications, Chief Sustainability Officer
Jamie Brannan
Executive Vice President, Chief Commercial Officer
Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Robert J. Polzer
Executive Vice President, President - Research and Development
Michael B. Mccallister
Non-Executive Independent Chairman of the Board
Gavin D. K. Hattersley
Director
Paul M. Bisaro
Independent Director
Vanessa Broadhurst
Independent Director
Frank A. D'amelio
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US98978V1035
  • Market cap
    $70.14bn
  • Employees
    13,800
  • Shares in issue
    501.21m
  • Exchange
    New York Stock Exchange
  • Index
    S&P 500, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.